The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 ...

CW Petroleum Corp (OTCQB: CWPE) (the 'Company” or 'CWPE”), a leading provider of Specialty Renewable and Hydrocarbon Motor ...

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) reported another quarter of double-digit revenue growth and solidified its ...